Website Development for Life Sciences: Communicating Complex Science Simply

Life sciences websites face a communication challenge most other industries don't: the same site frequently needs to serve investors evaluating the business, clinical partners assessing scientific credibility, and — for patient-facing biotech or pharma companies — patients trying to understand a treatment in plain terms, often all from the same underlying research and regulatory content. Getting this right means deliberately structuring the site around these distinct audiences, rather than writing one version of the content and hoping it serves everyone adequately.

How Life Sciences Websites Serve Both Scientific and General Audiences

The most effective approach layers content by depth rather than trying to write one version that satisfies both a research scientist and a general patient audience simultaneously — an approach that inevitably underserves one side or the other. This typically means plain-language summaries as the primary content for general audiences, with clear, well-signposted paths to deeper scientific or regulatory detail for audiences who want or need it (clinicians, investors, researchers). The key design principle is giving each audience a genuine, appropriate path through the same underlying information, rather than forcing everyone through identical content.

Do Life Sciences Websites Need Separate Sections for Investors and Patients?

Often, yes, at least at the navigation level — investors are typically looking for pipeline status, clinical trial progress, and financial or partnership information, while patients (where relevant) are looking for treatment information in accessible language. Structuring clear, separate navigation paths for these audiences, even when they draw from overlapping underlying content, generally serves both far better than a single generalized structure that makes either audience hunt for what they actually need.

What Regulatory Considerations Apply to Pharma or Biotech Website Content?

This varies significantly based on the specific company's regulatory status and what claims the content makes — pharmaceutical and biotech companies operate under real regulatory scrutiny (FDA and similar bodies, depending on jurisdiction) regarding how they can describe treatments, especially anything not yet fully approved, and what claims can be made publicly versus only to specific professional audiences. This is an area where legal and regulatory review of website content is essential, not optional, and should happen before content goes live, not as an afterthought once the site is built.

Should Life Sciences Websites Include Published Research or Clinical Data?

Generally, yes, particularly for building credibility with clinical and scientific audiences — links to published research, clinical trial registries, and peer-reviewed data provide the kind of verifiable, third-party-validated evidence that builds real trust with a technically sophisticated audience skeptical of unsubstantiated claims. For patient-facing content, this data is usually better summarized in accessible language with links to the full research for those who want to go deeper, rather than presented in raw technical form to a general audience.

The Broader Multi-Audience Design Challenge

This layered, audience-aware approach to complex information isn't unique to life sciences — it shows up in various specialized industries where a single website has to serve genuinely different audience needs. What makes life sciences particularly challenging is the combination of high scientific complexity, real regulatory stakes, and often life-or-health-relevant content for the patient-facing audience specifically, all at once. Getting the content architecture right from the start — deciding deliberately how different audiences will navigate to the content that's actually relevant to them — matters more here than in almost any other industry vertical.

For the closely related telehealth and virtual care technical requirements that many life sciences and healthcare companies also navigate, see our telemedicine website development guide.

Frequently Asked Questions

How do life sciences websites serve both scientific and general audiences?

By layering content by depth — plain-language summaries as primary content for general audiences, with clear paths to deeper scientific or regulatory detail for clinicians, investors, or researchers who want it, rather than one version trying to serve everyone.

Do life sciences websites need separate sections for investors and patients?

Often yes, at least at the navigation level, since investors and patients are typically looking for very different information (pipeline/financial data vs. treatment information) even when drawing from overlapping underlying content.

What regulatory considerations apply to pharma or biotech website content?

This varies by company and jurisdiction, but pharmaceutical and biotech companies face real regulatory scrutiny over how treatments can be described, especially anything not yet fully approved — legal and regulatory review before content goes live is essential.

Should life sciences websites include published research or clinical data?

Generally yes, particularly for building credibility with clinical and scientific audiences, though patient-facing content is usually better served by accessible summaries with links to the full research for those who want more depth.